{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Will be compared to historical controls of ixazomib citrate + dexamethasone. Responses to treatment will be measured by serum immunoglobulins, serum free kappa and lambda light chains, serum protein electrophoresis/immunofixation electrophoresis, and 24-hour urine protein electrophoresis/immunofixation. International uniform response criteria will be used. The anti-myeloma activity will be evaluated on an exploratory basis and will be summarized using descriptive statistics or graphical methods. No formal comparison will be carried forth.","groups":[{"description":"Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAbatacept: Given IV and SC\n\nDexamethasone: Given PO\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (Abatacept, Ixazomib Citrate, Dexamethasone)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 patient experienced death prior to disease response assessment.","reportingStatus":"POSTED","timeFrame":"1 cycle of 28 days","title":"Response Rate of Abatacept + Ixazomib Citrate + Dexamethasone in Multiple Myeloma Patients","type":"PRIMARY","unitOfMeasure":"Participants"}